Invezz

Cosmos Holdings (COSM)

Nasdaq Market Closed

Cosmos Health Inc., traded under the symbol COSM, is a diversified healthcare company with activities spanning pharmaceutical distribution, branded nutraceuticals, manufacturing, research and development, and digital health services. The business is vertically integrated, meaning it participates in several parts of the healthcare supply chain rather than operating only as a distributor or product owner.

The company’s largest operating area is wholesale distribution. Through this segment, Cosmos Health supplies pharmaceutical and healthcare products, including generic medicines, over-the-counter drugs, medical products, nutraceuticals, and other healthcare-related items. Wholesale activity gives the company exposure to demand from pharmacies, healthcare providers, and commercial partners, although margins in distribution can be competitive and sensitive to procurement and logistics costs.

Cosmos Health also owns and develops proprietary consumer health brands. Its nutraceutical lines include Sky Premium Life and Mediterranation, which are positioned around wellness, dietary supplementation, and lifestyle-related health needs. These branded products give the company an opportunity to build higher-recognition offerings alongside its distribution business.

In addition, the company is involved in pharmaceutical manufacturing and the development or repurposing of medicines. Its portfolio includes generics, OTC products, biocides, and nutraceuticals, while its broader healthcare strategy includes a telehealth platform. This mix reflects an effort to combine traditional pharmaceutical operations with consumer health and digital access to care.

Cosmos Health is distinctive for its broad, multi-channel approach within a small-cap healthcare framework. Its performance depends on product demand, supplier relationships, regulatory compliance, manufacturing execution, brand development, and its ability to scale higher-value healthcare products beyond wholesale distribution.

0.25 USD
0.25 USD
−0.01 (-5.48%)
Pre-market

Last updated

Market Cap
13.61M
P/E
P/FCF
P/S
0.2
Enterprise Value
30.71M
Sector
Health Care
Industry
Drugs, Drug Proprietaries, and Druggists' Sundries
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI, J3, 55438
GlobeNewswire Inc.

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

Oct 10, 2025, 08:00 AM
GlobeNewswire Inc.

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

Oct 03, 2025, 15:56 PM
GlobeNewswire Inc.

Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue

Sep 22, 2025, 08:00 AM
GlobeNewswire Inc.

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

Sep 11, 2025, 08:00 AM
GlobeNewswire Inc.

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

Aug 18, 2025, 12:45 PM
GlobeNewswire Inc.

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Apr 30, 2025, 12:50 PM
Investing.com

Cosmos Health secures new pharma manufacturing deals - Investing.com

Jul 18, 2024, 17:16 PM
Investing.com

Cosmos Health subsidiary secures Australian CBD product deal By Investing.com - Investing.com

Jul 09, 2024, 14:27 PM
Zacks Investment Research

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

May 29, 2024, 08:15 AM
Zacks Investment Research

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2024, 08:40 AM
Zacks Investment Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2024, 08:40 AM
Zacks Investment Research

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates

May 09, 2024, 17:25 PM
PennyStocks

5 Hot Penny Stocks To Watch Before Next Week

Apr 27, 2023, 15:09 PM
MarketWatch

Robinhood cleared to buy FTX founder Sam Bankman-Fried’s stock, sending shares higher

Feb 09, 2023, 12:19 PM
MarketWatch

Meme stocks and cannabis were investing fads, but Morgan Stanley says AI is the real deal

Feb 09, 2023, 08:32 AM
MarketWatch

Robinhood accidentally sold short on a meme stock and lost $57 million

Feb 09, 2023, 07:32 AM
MarketWatch

New York City scraps COVID vaccine mandate for public-sector workers. ‘This is the right moment for this decision,’ Mayor Adams says.

Feb 08, 2023, 08:42 AM
Seeking Alpha

Cosmos Health: A Cash-Rich Small Cap With Significant Growth Ahead

Jan 11, 2023, 00:01 AM
PennyStocks

Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch

Jan 03, 2023, 10:10 AM
MarketWatch

Stocks remain overpriced, even vs. the dot-com bubble. But you can still find good picks in these 2 sectors.

Dec 22, 2022, 09:54 AM
Market Cap
13.61M
Enterprise Value
30.71M
P/E
P/B
0.69
P/S
0.2
EV / EBITDA
-1.86
EV / Sales
0.44
EPS
-0.39
Dividend Yield
0%
P/FCF
P/CF
Free Cash Flow
-9.38M
ROE
-106.59%
ROA
-33.88%
Debt / Equity
0.89
Current Ratio
1.03
Quick Ratio
0.87
Cash
0.02
Avg Volume
1.08M
Fundamentals Snapshot Price
0.25

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 17.93M 19.7M 17.11M 14.75M 13.71M
Gross profit 1.38M 2.08M 2.6M 1.16M 2.05M
Operating income -2.18M -11.41M -1.82M -2.65M -833.15K
EBITDA -1.84M -10.92M -1.44M -2.29M -517.31K
Net income -2.81M -10.15M -5.35M -2.83M -818.1K
Basic EPS -0.06 -0.31 -0.17 -0.1 -0.03
Diluted EPS -0.06 -0.31 -0.17 -0.1 -0.03

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 62.37M 65.48M 69.49M 61.84M 57.19M
Total liabilities 42.54M 47.05M 46.36M 35.6M 31.24M
Total equity 19.83M 18.42M 23.13M 26.23M 25.95M
Cash & equivalents 514.7K 715.67K 889.44K 655.5K 742.88K
Current assets 35.25M 35.64M 34.36M 30.56M 27.84M
Current liabilities 34.08M 38.27M 38.53M 31.17M 26.59M

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow -1.07M -4.6M -2.46M -1.21M -186.32K
Investing cash flow -708.96K -1.07M -1.01M 71.82K -7.07K
Financing cash flow 347.63K 4.7M 7.19M 1.6M 560.86K
Change in cash -1.3M -1.17M 3.98M -87.38K 427.78K
Kind Filing Date Link
edgar index DEF 14A — Cosmos Health Inc. View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
edgar index PRE 14A — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 10-Q — Cosmos Health Inc. View Filing
edgar index NT 10-Q — Cosmos Health Inc. View Filing
edgar index RW — Cosmos Health Inc. View Filing
edgar index S-3/A — Cosmos Health Inc. View Filing
edgar index SCHEDULE 13G/A — Cosmos Health Inc. View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 10-K — Cosmos Health Inc. View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
edgar index NT 10-K — Cosmos Health Inc. View Filing
edgar index SCHEDULE 13G/A — Cosmos Health Inc. View Filing
edgar index 4 — Cosmos Health Inc. View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index S-3/A — Cosmos Health Inc. View Filing
edgar index 4 — Cosmos Health Inc. View Filing
edgar index 424B3 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 4 — Cosmos Health Inc. View Filing
form 4 Form 4 — Siokas Grigorios View Filing
form 4 Form 4 — Siokas Grigorios View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 10-Q — Cosmos Health Inc. View Filing
edgar index S-3 — Cosmos Health Inc. View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — Cosmos Health Inc. View Filing
edgar index DEFA14A — Cosmos Health Inc. View Filing
eight k text 8-K — 8-K View Filing
edgar index S-3/A — Cosmos Health Inc. View Filing
edgar index S-3 — Cosmos Health Inc. View Filing
edgar index 424B3 — Cosmos Health Inc. View Filing
edgar index DEF 14A — Cosmos Health Inc. View Filing
edgar index SCHEDULE 13G/A — Cosmos Health Inc. View Filing
edgar index 10-Q — Cosmos Health Inc. View Filing
edgar index NT 10-Q — Cosmos Health Inc. View Filing
edgar index SCHEDULE 13G/A — Cosmos Health Inc. View Filing
edgar index PRE 14A — Cosmos Health Inc. View Filing